Avaliação da atividade in vitro dos novos antimicrobianos da classe das fluoroquinolonas, cefalosporinas e carbapenens contra 569 amostras clínicas de bactérias gram-negativas
Autor(a) principal: | |
---|---|
Data de Publicação: | 1997 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Institucional da UNIFESP |
Texto Completo: | http://dx.doi.org/10.1590/S0104-42301997000200010 http://repositorio.unifesp.br/handle/11600/492 |
Resumo: | OBJECTIVE. Evaluation of the in vitro activity of new fluoroquinolones, cephalosporins and carbapenems against gram-negative bacteria. MATERIAL AND METHOD. A total of 569 clinical isolates were obtained from inpatients at São Paulo Hospital - UNIFESP/EPM in June and July of 1992. The species distribution was as follows: Enterobacter sp. (62), Escherichia coli (308), Klebsiella pneumoniae (27), Klebsiella sp. (9), Proteus mirabilis (23), Pseudomonas aeruginosa (88), Pseudomonas sp. (4), Serratia sp. (30) and other gram-negatives (7). Susceptibility tests were performed by broth microdilution. The antimicrobials agents tested were: ciprofloxacin, ofloxacin, levofloxacin, grepafloxacin, DU 6859-a, ceftazidime, cefepime, FK 037, imipenem, meropenem and biapenem. RESULTS. DU 6859-a showed the highest antimicrobial activity among the fluoroquinolones. It was two- to four-fold more active than ciprofloxacin against some species. The potency and antimicrobial spectrum were similar between the fourth-generation cephalosporins against Enterobacteriaceae, except for Enterobacter sp. strains which were more susceptible to cefepime than they were to cefetazidime or FK 037. When testing Pseudomonas aeruginosa, ceftazidime was slightly more active than the other cephalosporins. Against Enterobacteriaceae and Pseudomonas aeruginosa strains, meropenem was more active than imipenem or biapenem. In addition, the percentage of strains, susceptible to meropenem was higher than the percentage susceptible to the other cerbapenems against these species. CONCLUSION. The new antimicrobial agents demonstrated in vitro activity higher than that of agents commercially avaliable. However, more studies are necessary to further evaluate the in vivo activity and the clinical benefit of these compounds. |
id |
UFSP_b215606eebab8cba6ca93b067e99d11d |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br/:11600/492 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
Avaliação da atividade in vitro dos novos antimicrobianos da classe das fluoroquinolonas, cefalosporinas e carbapenens contra 569 amostras clínicas de bactérias gram-negativasEvaluation of in vitro activity of new fluoroquinolones, cephalosporins and carbapenems against 569 gram-negative bacteriaIn vitro activityGram-negative bacteriaFluoroquinolonesCephalosporinsCarbapenemsAtividade in vitroBactérias gram-negativasFluoroquinolonasCefalosporinasCarbapenensOBJECTIVE. Evaluation of the in vitro activity of new fluoroquinolones, cephalosporins and carbapenems against gram-negative bacteria. MATERIAL AND METHOD. A total of 569 clinical isolates were obtained from inpatients at São Paulo Hospital - UNIFESP/EPM in June and July of 1992. The species distribution was as follows: Enterobacter sp. (62), Escherichia coli (308), Klebsiella pneumoniae (27), Klebsiella sp. (9), Proteus mirabilis (23), Pseudomonas aeruginosa (88), Pseudomonas sp. (4), Serratia sp. (30) and other gram-negatives (7). Susceptibility tests were performed by broth microdilution. The antimicrobials agents tested were: ciprofloxacin, ofloxacin, levofloxacin, grepafloxacin, DU 6859-a, ceftazidime, cefepime, FK 037, imipenem, meropenem and biapenem. RESULTS. DU 6859-a showed the highest antimicrobial activity among the fluoroquinolones. It was two- to four-fold more active than ciprofloxacin against some species. The potency and antimicrobial spectrum were similar between the fourth-generation cephalosporins against Enterobacteriaceae, except for Enterobacter sp. strains which were more susceptible to cefepime than they were to cefetazidime or FK 037. When testing Pseudomonas aeruginosa, ceftazidime was slightly more active than the other cephalosporins. Against Enterobacteriaceae and Pseudomonas aeruginosa strains, meropenem was more active than imipenem or biapenem. In addition, the percentage of strains, susceptible to meropenem was higher than the percentage susceptible to the other cerbapenems against these species. CONCLUSION. The new antimicrobial agents demonstrated in vitro activity higher than that of agents commercially avaliable. However, more studies are necessary to further evaluate the in vivo activity and the clinical benefit of these compounds.OBJETIVO. A proposta deste estudo foi a avaliação da atividade in vitro de novos antimicrobianos da classe das fluoroquinolonas, das cefalosporinas e dos carbapenens contra bactérias gram-negativas. MATERIAL E MÉTODO. Foram avaliadas 569 amostras clínicas isoladas no Hospital São Paulo - UNIFESP/EPM, no período compreendido entre junho e julho de 1992. A distribuição das espécies foi: Enterobacter sp. (62), Escherichia coli (308), Klebsiella pneumoniae (27), Klebsiella sp. (9), Proteus mirabilis (23), Pseudomonas aeruginosa (88), Pseudomonas sp. (4), Serratia sp. (30) e outros gram-negativos (7). Os testes de sensibilidade aos antimicrobianos avaliados (ciprofloxacina, ofloxacina, levofloxacina, grepafloxacina, DU 6859-a, ceftazidima, cefepima, FK 037, imipenem, meropenem e biapenem) foram realizados pela técnica de microdiluição em caldo. RESULTADOS. A fluoroquinolona mais potente foi a DU 6859-a; em algumas amostras, apresentou potência duas a quatro vezes superior àquela apresentada pela ciprofloxacina. As novas cefalosporinas de 4ª geração apresentaram potência e espectro de ação semelhantes nas amostras de Enterobacteriaceae, com exceção das amostras de Enterobacter sp., para as quais a cefepima foi mais ativa, e das amostras de P. aeruginosa, para as quais a cefalosporina mais potente e com maior percentagem de suscetibilidade foi a ceftazidima. O meropenem foi o carbapenem mais potente e com maior percentagem de suscetibilidade nas amostras estudadas. CONCLUSÃO. As novas drogas apresentaram, em geral, melhor atividade in vitro do que drogas da mesma classe já utilizadas na prática clínica. Porém, mais estudos serão necessários para avaliar a atividade in vivo desses agentes e sua real utilidade clínica.Universidade Federal de São Paulo (UNIFESP) Escola Paulista de Medicina Laboratório Especial de Microbiologia ClínicaUNIFESP, EPM, Laboratório Especial de Microbiologia ClínicaSciELOAssociação Médica BrasileiraUniversidade Federal de São Paulo (UNIFESP)Gales, Ana Cristina [UNIFESP]Pignatari, Antonio Carlos Campos [UNIFESP]Jones, R.n. [UNIFESP]Baretta, M. [UNIFESP]Sader, Helio Silva [UNIFESP]2015-06-14T13:24:36Z2015-06-14T13:24:36Z1997-06-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion137-144application/pdfhttp://dx.doi.org/10.1590/S0104-42301997000200010Revista da Associação Médica Brasileira. Associação Médica Brasileira, v. 43, n. 2, p. 137-144, 1997.10.1590/S0104-42301997000200010S0104-42301997000200010.pdf0104-4230S0104-42301997000200010http://repositorio.unifesp.br/handle/11600/492porRevista da Associação Médica Brasileirainfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-08-06T03:26:14Zoai:repositorio.unifesp.br/:11600/492Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-08-06T03:26:14Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.none.fl_str_mv |
Avaliação da atividade in vitro dos novos antimicrobianos da classe das fluoroquinolonas, cefalosporinas e carbapenens contra 569 amostras clínicas de bactérias gram-negativas Evaluation of in vitro activity of new fluoroquinolones, cephalosporins and carbapenems against 569 gram-negative bacteria |
title |
Avaliação da atividade in vitro dos novos antimicrobianos da classe das fluoroquinolonas, cefalosporinas e carbapenens contra 569 amostras clínicas de bactérias gram-negativas |
spellingShingle |
Avaliação da atividade in vitro dos novos antimicrobianos da classe das fluoroquinolonas, cefalosporinas e carbapenens contra 569 amostras clínicas de bactérias gram-negativas Gales, Ana Cristina [UNIFESP] In vitro activity Gram-negative bacteria Fluoroquinolones Cephalosporins Carbapenems Atividade in vitro Bactérias gram-negativas Fluoroquinolonas Cefalosporinas Carbapenens |
title_short |
Avaliação da atividade in vitro dos novos antimicrobianos da classe das fluoroquinolonas, cefalosporinas e carbapenens contra 569 amostras clínicas de bactérias gram-negativas |
title_full |
Avaliação da atividade in vitro dos novos antimicrobianos da classe das fluoroquinolonas, cefalosporinas e carbapenens contra 569 amostras clínicas de bactérias gram-negativas |
title_fullStr |
Avaliação da atividade in vitro dos novos antimicrobianos da classe das fluoroquinolonas, cefalosporinas e carbapenens contra 569 amostras clínicas de bactérias gram-negativas |
title_full_unstemmed |
Avaliação da atividade in vitro dos novos antimicrobianos da classe das fluoroquinolonas, cefalosporinas e carbapenens contra 569 amostras clínicas de bactérias gram-negativas |
title_sort |
Avaliação da atividade in vitro dos novos antimicrobianos da classe das fluoroquinolonas, cefalosporinas e carbapenens contra 569 amostras clínicas de bactérias gram-negativas |
author |
Gales, Ana Cristina [UNIFESP] |
author_facet |
Gales, Ana Cristina [UNIFESP] Pignatari, Antonio Carlos Campos [UNIFESP] Jones, R.n. [UNIFESP] Baretta, M. [UNIFESP] Sader, Helio Silva [UNIFESP] |
author_role |
author |
author2 |
Pignatari, Antonio Carlos Campos [UNIFESP] Jones, R.n. [UNIFESP] Baretta, M. [UNIFESP] Sader, Helio Silva [UNIFESP] |
author2_role |
author author author author |
dc.contributor.none.fl_str_mv |
Universidade Federal de São Paulo (UNIFESP) |
dc.contributor.author.fl_str_mv |
Gales, Ana Cristina [UNIFESP] Pignatari, Antonio Carlos Campos [UNIFESP] Jones, R.n. [UNIFESP] Baretta, M. [UNIFESP] Sader, Helio Silva [UNIFESP] |
dc.subject.por.fl_str_mv |
In vitro activity Gram-negative bacteria Fluoroquinolones Cephalosporins Carbapenems Atividade in vitro Bactérias gram-negativas Fluoroquinolonas Cefalosporinas Carbapenens |
topic |
In vitro activity Gram-negative bacteria Fluoroquinolones Cephalosporins Carbapenems Atividade in vitro Bactérias gram-negativas Fluoroquinolonas Cefalosporinas Carbapenens |
description |
OBJECTIVE. Evaluation of the in vitro activity of new fluoroquinolones, cephalosporins and carbapenems against gram-negative bacteria. MATERIAL AND METHOD. A total of 569 clinical isolates were obtained from inpatients at São Paulo Hospital - UNIFESP/EPM in June and July of 1992. The species distribution was as follows: Enterobacter sp. (62), Escherichia coli (308), Klebsiella pneumoniae (27), Klebsiella sp. (9), Proteus mirabilis (23), Pseudomonas aeruginosa (88), Pseudomonas sp. (4), Serratia sp. (30) and other gram-negatives (7). Susceptibility tests were performed by broth microdilution. The antimicrobials agents tested were: ciprofloxacin, ofloxacin, levofloxacin, grepafloxacin, DU 6859-a, ceftazidime, cefepime, FK 037, imipenem, meropenem and biapenem. RESULTS. DU 6859-a showed the highest antimicrobial activity among the fluoroquinolones. It was two- to four-fold more active than ciprofloxacin against some species. The potency and antimicrobial spectrum were similar between the fourth-generation cephalosporins against Enterobacteriaceae, except for Enterobacter sp. strains which were more susceptible to cefepime than they were to cefetazidime or FK 037. When testing Pseudomonas aeruginosa, ceftazidime was slightly more active than the other cephalosporins. Against Enterobacteriaceae and Pseudomonas aeruginosa strains, meropenem was more active than imipenem or biapenem. In addition, the percentage of strains, susceptible to meropenem was higher than the percentage susceptible to the other cerbapenems against these species. CONCLUSION. The new antimicrobial agents demonstrated in vitro activity higher than that of agents commercially avaliable. However, more studies are necessary to further evaluate the in vivo activity and the clinical benefit of these compounds. |
publishDate |
1997 |
dc.date.none.fl_str_mv |
1997-06-01 2015-06-14T13:24:36Z 2015-06-14T13:24:36Z |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.1590/S0104-42301997000200010 Revista da Associação Médica Brasileira. Associação Médica Brasileira, v. 43, n. 2, p. 137-144, 1997. 10.1590/S0104-42301997000200010 S0104-42301997000200010.pdf 0104-4230 S0104-42301997000200010 http://repositorio.unifesp.br/handle/11600/492 |
url |
http://dx.doi.org/10.1590/S0104-42301997000200010 http://repositorio.unifesp.br/handle/11600/492 |
identifier_str_mv |
Revista da Associação Médica Brasileira. Associação Médica Brasileira, v. 43, n. 2, p. 137-144, 1997. 10.1590/S0104-42301997000200010 S0104-42301997000200010.pdf 0104-4230 S0104-42301997000200010 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
Revista da Associação Médica Brasileira |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
137-144 application/pdf |
dc.publisher.none.fl_str_mv |
Associação Médica Brasileira |
publisher.none.fl_str_mv |
Associação Médica Brasileira |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
biblioteca.csp@unifesp.br |
_version_ |
1814268407103619072 |